PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook

被引：10

作者：

Di Bartolo, Belinda ^{[1
]}

Scherer, Daniel J. ^{[1
]}

Brown, Alex ^{[1
]}

Psaltis, Peter J. ^{[1
]}

Nicholls, Stephen J. ^{[1
]}

机构：

[1] Univ Adelaide, South Australian Hlth & Med Res Inst, POB 11060, Adelaide, SA 5001, Australia

来源：

BIODRUGS | 2017年 / 31卷 / 03期

关键词：

SUBTILISIN/KEXIN TYPE 9; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; HIGH CARDIOVASCULAR RISK; MONOCLONAL-ANTIBODY; RANDOMIZED-TRIAL; LDL CHOLESTEROL; LIPOPROTEIN METABOLISM; INTOLERANT PATIENTS; CORONARY-DISEASE; REDUCING LIPIDS;

D O I：

10.1007/s40259-017-0220-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The clinical reality of residual risk despite statin (HMG-CoA reductase inhibitor) therapy and emergence of statin intolerance support the need to develop additional lipid-lowering strategies. Proprotein convertase subtilisin kexin type 9 (PCSK9) has received considerable attention by virtue of genetic and clinical studies that have revealed its pivotal role in the regulation of cholesterol homeostasis. Monoclonal antibodies have been developed targeting PCSK9, which have been demonstrated to produce profound low-density lipoprotein cholesterol (LDL-C) lowering when provided as monotherapy or in combination with statins. With the reports that the PCSK9 inhibitor evolocumab has a favorable impact on both plaque progression and cardiovascular outcomes, these findings begin to translate the benefits of PCSK9 inhibition from lipids to the vessel wall and ultimately to clinical outcomes. The clinical implications for the use of these agents are reviewed in this article.

引用

页码：167 / 174

页数：8

共 55 条

[31] Effect of very high-intensity statin therapy on regression of coronary atherosclerosis - The ASTEROID trial [J].

Nissen, SE ;

Nicholls, SJ ;

Sipahi, I ;

Libby, P ;

Raichlen, JS ;

Ballantyne, CM ;

Davignon, J ;

Erbel, R ;

Fruchart, JC ;

Tardif, JC ;

Schoenhagen, P ;

Crowe, T ;

Cain, V ;

Wolski, K ;

Goormastic, M ;

Tuzcu, EM .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (13) :1556-1565

[32] Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance The GAUSS-3 Randomized Clinical Trial [J].

Nissen, Steven E. ;

Stroes, Erik ;

Dent-Acosta, Ricardo E. ;

Rosenson, Robert S. ;

Lehman, Sam J. ;

Sattar, Naveed ;

Preiss, David ;

Bruckert, Eric ;

Ceska, Richard ;

Lepor, Norman ;

Ballantyne, Christie M. ;

Gouni-Berthold, Ioanna ;

Elliott, Mary ;

Brennan, Danielle M. ;

Wasserman, Scott M. ;

Somaratne, Ransi ;

Scott, Rob ;

Stein, Evan A. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (15) :1580-1590

[33] PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role [J].

Raal, Frederick J. ;

Giugliano, Robert P. ;

Sabatine, Marc S. ;

Koren, Michael J. ;

Blom, Dirk ;

Seidah, Nabil G. ;

Honarpour, Narimon ;

Lira, Armando ;

Xue, Allen ;

Chiruvolu, Padmaja ;

Jackson, Simon ;

Di, Mei ;

Peach, Matthew ;

Somaratne, Ransi ;

Wasserman, Scott M. ;

Scott, Rob ;

Stein, Evan A. .

JOURNAL OF LIPID RESEARCH, 2016, 57 (06) :1086-1096

[34] PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial [J].

Raal, Frederick J. ;

Stein, Evan A. ;

Dufour, Robert ;

Turner, Traci ;

Civeira, Fernando ;

Burgess, Lesley ;

Langslet, Gisle ;

Scott, Russell ;

Olsson, Anders G. ;

Sullivan, David ;

Hovingh, G. Kees ;

Cariou, Bertrand ;

Gouni-Berthold, Ioanna ;

Somaratne, Ransi ;

Bridges, Ian ;

Scott, Rob ;

Wasserman, Scott M. ;

Gaudet, Daniel .

LANCET, 2015, 385 (9965) :331-340

[35] Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial [J].

Raal, Frederick J. ;

Honarpour, Narimon ;

Blom, Dirk J. ;

Hovingh, G. Kees ;

Xu, Feng ;

Scott, Rob ;

Wasserman, Scott M. ;

Stein, Evan A. ;

Investigators, T. E. S. L. A. .

LANCET, 2015, 385 (9965) :341-350

[36] Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol [J].

Ray, Kausik K. ;

Landmesser, Ulf ;

Leiter, Lawrence A. ;

Kallend, David ;

Dufour, Robert ;

Karakas, Mahir ;

Hall, Tim ;

Troquay, Roland P. T. ;

Turner, Traci ;

Visseren, Frank L. J. ;

Wijngaard, Peter ;

Wright, R. Scott ;

Kastelein, John J. P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (15) :1430-1440

[37] Reductions in Atherogenic Lipids and Major Cardiovascular Events A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control [J].

Ray, Kausik K. ;

Ginsberg, Henry N. ;

Davidson, Michael H. ;

Pordy, Robert ;

Bessac, Laurence ;

Minini, Pascal ;

Eckel, Robert H. ;

Cannon, Christopher P. .

CIRCULATION, 2016, 134 (24) :1931-+

[38] Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans [J].

Reyes-Soffer, Gissette ;

Pavlyha, Marianna ;

Ngai, Colleen ;

Thomas, Tiffany ;

Holleran, Stephen ;

Ramakrishnan, Rajasekhar ;

Karmally, Wahida ;

Nandakumar, Renu ;

Fontanez, Nelson ;

Obunike, Joseph ;

Marcovina, Santica M. ;

Lichtenstein, Alice H. ;

Matthan, Nirupa R. ;

Matta, James ;

Maroccia, Magali ;

Becue, Frederic ;

Poitiers, Franck ;

Swanson, Brian ;

Cowan, Lisa ;

Sasiela, William J. ;

Surks, Howard K. ;

Ginsberg, Henry N. .

CIRCULATION, 2017, 135 (04) :352-+

[39] Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients [J].

Ridker, P. M. ;

Revkin, J. ;

Amarenco, P. ;

Brunell, R. ;

Curto, M. ;

Civeira, F. ;

Flather, M. ;

Glynn, R. J. ;

Gregoire, J. ;

Jukema, J. W. ;

Karpov, Y. ;

Kastelein, J. J. P. ;

Koenig, W. ;

Lorenzatti, A. ;

Manga, P. ;

Masiukiewicz, U. ;

Miller, M. ;

Mosterd, A. ;

Murin, J. ;

Nicolau, J. C. ;

Nissen, S. ;

Ponikowski, P. ;

Santos, R. D. ;

Schwartz, P. F. ;

Soran, H. ;

White, H. ;

Wright, R. S. ;

Vrablik, M. ;

Yunis, C. ;

Shear, C. L. ;

Tardif, J. -C. ;

Conde, Diego ;

Colquhoun, David ;

Missault, Luc ;

Gregoire, Jean ;

Gao, Runlin ;

Urina, Miguel ;

Solar, Miroslav ;

Jensen, Henrik Kjaerulf ;

Grobbee, Diederick ;

Savolainen, Markku ;

Schiele, Francois ;

Montalescot, Gilles ;

Edes, Istvan ;

Blake, Gavin ;

Lotan, Chaim ;

Maggioni, Aldo ;

Savonitto, Stefano ;

Lee, Cheol Whan ;

Leiva Pons, Jose Luis .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (16) :1527-1539

[40] Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials [J].

Ridker, Paul M. ;

Amarenco, Pierre ;

Brunell, Robert ;

Glynn, Robert J. ;

Jukema, J. Wouter ;

Kastelein, John J. P. ;

Koenig, Wolfgang ;

Nissen, Steven ;

Revkin, James ;

Santos, Raul D. ;

Schwartz, Pamela F. ;

Yunis, Carla ;

Tardif, Jean-Claude .

AMERICAN HEART JOURNAL, 2016, 178 :135-144

← 1 2 3 4 5 6 →